ZYME · NASDAQ
Zymeworks Inc.
$28.55 -0.22 (-0.77%)
Company overview
Zymeworks Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidate, zanidatamab, is a novel bispecific antibody in Phase 1 and Phase 2 clinical trials for biliary tract cancer, gastroesophageal adenocarcinomas, breast cancer, and colorectal cancer. ZW49 is a biparatopic anti-HER2 antibody-drug conjugate in Phase 1 clinical trials for advanced or metastatic HER2-expressing tumors. Zymeworks has strategic partnerships with Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb Company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $2B
- Employees
- 299
- Headquarters
- Middletown, BC
- Website
- zymeworks.com
- CEO
- Kenneth H. Galbraith
- Listed
- April 28, 2017
- P/E
- -20.85
- Dividend yield
- 0.00%
Company financials
- Revenue
- $81.3M
- Gross profit
- $76.7M
- Operating income
- -$114M
- EBITDA
- -$111M
- Net income
- -$103M
- EPS
- -$1.37
- Total assets
- $478M
- Total debt
- $17M
- Gross margin
- 94.42%
- Net margin
- -126.33%
- Earnings yield
- -4.80%
No geographic segmentation.
Showing FY 2025
ZYME
1D
NASDAQ
O28.41H28.43L27.42C28.22-0.22 (-0.77%)Vol238.09K